VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 30, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today reported its audited operating results for 2006 and updated its 2007 plans to advance three Phase II clinical trials that will determine the effectiveness of its products as treatments for the causes of Alzheimer's disease and other neurodegenerative conditions.
